( LEXINGTON Mass.--(BUSINESS WIRE)--Apr ...)EPIX Pharmaceuticals Announces Statistically Significant Results in,Cognitive Function from Phase 1b Clinical Trial of Novel 5-HT6 Drug,Candidate,Health

LEXINGTON, Mass.--(BUSINESS WIRE)--Apr 18, 2007 - EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX) announced today positive cognitive function results from its Phase 1b multiple ascending dose clinical trial of PRX-07034, the company's internally-discovered, novel 5-HT6 antagonist being developed for obesity, Alzheimer's disease and cognitive impairment associated with schizophrenia.

The randomized, double-blind, placebo-controlled Phase 1b, multiple ascending dose clinical trial was designed to study the safety, tolerability, pharmacokinetics, and pharmacodynamics of PRX-07034 administered orally once-daily for 28 days in a population of obese, but otherwise healthy, adults (average weight 100kg or 220 pounds). The 33-person trial, which was conducted in an in-patient setting, included measures to assess potential effects on cognitive function and obesity. Highlights from the study include: -0-

-- Primary endpoint: safety and tolerability.


    -- PRX-07034 was well tolerated up to 600 mg once per day. No dose

       limiting toxicity was identified, and no serious adverse events

       were reported. There were no withdrawals due to adverse events.


    -- PRX-07034 demonstrated predictable pharmacokinetics with dose

       proportional increases in exposures, and a half-life supporting

       once-daily administration.


-- Secondary endpoint: cognitive function (CogScreen(TM) test

   battery).


    -- Overall results on cognitive function showed a dose-dependent

       trend for improvement associated with PRX-07034.


    -- For the predetermined endpoint that combines speed and

       accuracy, there was a dose-dependent effect which was

       statistically significant (p=0.014 vs. placebo) at the 600 mg

       dose.


-- Additional findings: signals suggestive of pharmacologic activity

   were observed for obesity, even in the in-patient setting.


    -- A greater proportion of subjects on drug experienced weight

       loss during the o
'"/>




Page: 1 2 3 4 
Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird
Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging
Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin
Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin
Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials &
Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III
Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results
and Additional Oral and Poster Presentations at the XXI Congress of
the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib
Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4
Inhibitor, ARI-2243, at the ADA